Overview
The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia
Eligibility
Inclusion Criteria
- Participants must have a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the Diagnostic and Statistical Manual of Mental Disorders⎯Fifth Edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI).
- Participants must have a PANSS total score between 80 and 120, inclusive.
- Participants must have a CGI-S score of ≥ 4.
Exclusion Criteria
- Participants must not have any primary DSM-5 disorder other than schizophrenia within 12 months before screening.
- Participants must not be newly diagnosed or experiencing their first treated episode of schizophrenia.
- Participants must not have any history or presence of clinically significant medical conditions.
- Other protocol-defined Inclusion/Exclusion criteria apply.